Evaluation of cabotegravir plus rilpivirine in routine clinical settings in Japan: A multicentre study of efficacy, safety and biomarker dynamics
This study provides the first multicentre real-world data on CAB+RPV in Japan, demonstrating high virological outcomes among a significant portion of Japanese people with HIV. The findings suggest that CAB+RPV maintains a favourable safety profile, with no significant effects on chronic inflammation.
Authors
- Rumi Minami (ORCID: https://orcid.org/0000-0002-5847-4108)
- Mayumi Imahashi (ORCID: https://orcid.org/0000-0003-3464-4106)
- Hideta Nakamura (ORCID: https://orcid.org/0000-0001-7686-4604)
- Kazuaki Fukushima (ORCID: https://orcid.org/0000-0001-8986-6879)
- Ryoko Sekiya
- Michinori Shirano (ORCID: https://orcid.org/0009-0007-6421-7478)
- Yusuke Yoshino (ORCID: https://orcid.org/0000-0002-3633-4243)
- Toshibumi Taniguchi (ORCID: https://orcid.org/0000-0002-7732-9870)
- Eisuke Adachi (ORCID: https://orcid.org/0000-0002-1623-873X)
Institutions
- National Kyushu Medical Center (JP)
- Tokyo Metropolitan Komagome Hospital (JP)
- University of the Ryukyus (JP)
- Osaka City General Hospital (JP)
- Chiba University Hospital (JP)
- University of Tokyo Hospital (JP)
- Nagoya Medical Center (JP)
- Teikyo University (JP)
Publication Details
- Journal
- HIV Medicine
- Published
- 2025-08-09
- DOI
- https://doi.org/10.1111/hiv.70096
- Citations
- 1
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.40